vs
Side-by-side financial comparison of PARK AEROSPACE CORP (PKE) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
PARK AEROSPACE CORP is the larger business by last-quarter revenue ($17.3M vs $9.1M, roughly 1.9× Protalix BioTherapeutics, Inc.). PARK AEROSPACE CORP runs the higher net margin — 17.0% vs -60.3%, a 77.4% gap on every dollar of revenue. On growth, PARK AEROSPACE CORP posted the faster year-over-year revenue change (20.3% vs -49.9%). PARK AEROSPACE CORP produced more free cash flow last quarter ($4.3M vs $1.6M). Over the past eight quarters, PARK AEROSPACE CORP's revenue compounded faster (3.0% CAGR vs -6.7%).
Park Electrochemical Corp, now called the Park Aerospace Corp, is a Melville, New York-based materials manufacturer for the telecommunications, Internet infrastructure, high-end computing, and aerospace industries. It produces high-technology digital and radio frequency(RF)/microwave printed circuit material products, composite materials. Its printed circuit materials are used for complex multilayer printed circuit boards and other electronic interconnection systems, such as multilayer back-p...
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
PKE vs PLX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.3M | $9.1M |
| Net Profit | $3.0M | $-5.5M |
| Gross Margin | 34.1% | 49.4% |
| Operating Margin | 21.0% | -51.1% |
| Net Margin | 17.0% | -60.3% |
| Revenue YoY | 20.3% | -49.9% |
| Net Profit YoY | 87.1% | -184.8% |
| EPS (diluted) | $0.15 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.3M | $9.1M | ||
| Q3 25 | $16.4M | $17.9M | ||
| Q2 25 | $15.4M | $15.7M | ||
| Q1 25 | $16.9M | $10.1M | ||
| Q4 24 | $14.4M | $18.2M | ||
| Q3 24 | $16.7M | $18.0M | ||
| Q2 24 | $14.0M | $13.5M | ||
| Q1 24 | $16.3M | — |
| Q4 25 | $3.0M | $-5.5M | ||
| Q3 25 | $2.4M | $2.4M | ||
| Q2 25 | $2.1M | $164.0K | ||
| Q1 25 | $1.2M | $-3.6M | ||
| Q4 24 | $1.6M | $6.5M | ||
| Q3 24 | $2.1M | $3.2M | ||
| Q2 24 | $993.0K | $-2.2M | ||
| Q1 24 | $2.7M | — |
| Q4 25 | 34.1% | 49.4% | ||
| Q3 25 | 31.2% | 53.4% | ||
| Q2 25 | 30.6% | 62.5% | ||
| Q1 25 | 29.3% | 19.1% | ||
| Q4 24 | 26.6% | 78.7% | ||
| Q3 24 | 28.5% | 53.4% | ||
| Q2 24 | 29.3% | 29.8% | ||
| Q1 24 | 27.3% | — |
| Q4 25 | 21.0% | -51.1% | ||
| Q3 25 | 17.4% | 11.9% | ||
| Q2 25 | 15.7% | 7.5% | ||
| Q1 25 | 16.8% | -41.0% | ||
| Q4 24 | 12.8% | 39.6% | ||
| Q3 24 | 15.7% | 22.2% | ||
| Q2 24 | 14.9% | -18.0% | ||
| Q1 24 | 15.7% | — |
| Q4 25 | 17.0% | -60.3% | ||
| Q3 25 | 14.7% | 13.2% | ||
| Q2 25 | 13.5% | 1.0% | ||
| Q1 25 | 7.4% | -35.8% | ||
| Q4 24 | 10.9% | 35.6% | ||
| Q3 24 | 12.4% | 18.0% | ||
| Q2 24 | 7.1% | -16.4% | ||
| Q1 24 | 16.3% | — |
| Q4 25 | $0.15 | $-0.06 | ||
| Q3 25 | $0.12 | $0.03 | ||
| Q2 25 | $0.10 | $0.00 | ||
| Q1 25 | $0.06 | $-0.05 | ||
| Q4 24 | $0.08 | $0.10 | ||
| Q3 24 | $0.10 | $0.03 | ||
| Q2 24 | $0.05 | $-0.03 | ||
| Q1 24 | $0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.6M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.6M | $48.2M |
| Total Assets | $118.1M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.6M | $14.7M | ||
| Q3 25 | $61.6M | $13.6M | ||
| Q2 25 | $65.6M | $17.9M | ||
| Q1 25 | $68.8M | $19.5M | ||
| Q4 24 | $70.0M | $19.8M | ||
| Q3 24 | $72.0M | $27.4M | ||
| Q2 24 | $74.4M | $23.4M | ||
| Q1 24 | $77.2M | — |
| Q4 25 | $106.6M | $48.2M | ||
| Q3 25 | $105.8M | $52.9M | ||
| Q2 25 | $105.0M | $49.9M | ||
| Q1 25 | $107.2M | $45.2M | ||
| Q4 24 | $107.4M | $43.2M | ||
| Q3 24 | $110.3M | $32.4M | ||
| Q2 24 | $111.7M | $28.6M | ||
| Q1 24 | $112.9M | — |
| Q4 25 | $118.1M | $82.3M | ||
| Q3 25 | $116.4M | $82.3M | ||
| Q2 25 | $120.7M | $78.5M | ||
| Q1 25 | $122.1M | $73.9M | ||
| Q4 24 | $124.2M | $73.4M | ||
| Q3 24 | $125.1M | $61.6M | ||
| Q2 24 | $129.4M | $91.5M | ||
| Q1 24 | $132.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.1M | $2.0M |
| Free Cash FlowOCF − Capex | $4.3M | $1.6M |
| FCF MarginFCF / Revenue | 24.6% | 17.8% |
| Capex IntensityCapex / Revenue | 4.8% | 4.4% |
| Cash ConversionOCF / Net Profit | 1.73× | — |
| TTM Free Cash FlowTrailing 4 quarters | $3.4M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $2.0M | ||
| Q3 25 | $-2.1M | $-3.7M | ||
| Q2 25 | $1.6M | $-5.2M | ||
| Q1 25 | $969.0K | $-5.1M | ||
| Q4 24 | $2.7M | $4.0M | ||
| Q3 24 | $1.4M | $4.1M | ||
| Q2 24 | $-423.0K | $-3.6M | ||
| Q1 24 | $5.3M | — |
| Q4 25 | $4.3M | $1.6M | ||
| Q3 25 | $-2.3M | $-4.2M | ||
| Q2 25 | $1.1M | $-5.7M | ||
| Q1 25 | $338.0K | $-5.4M | ||
| Q4 24 | $2.7M | $3.6M | ||
| Q3 24 | $1.3M | $4.0M | ||
| Q2 24 | $-435.0K | $-3.8M | ||
| Q1 24 | $5.1M | — |
| Q4 25 | 24.6% | 17.8% | ||
| Q3 25 | -14.0% | -23.7% | ||
| Q2 25 | 7.2% | -36.2% | ||
| Q1 25 | 2.0% | -53.0% | ||
| Q4 24 | 18.6% | 19.6% | ||
| Q3 24 | 7.5% | 22.4% | ||
| Q2 24 | -3.1% | -28.1% | ||
| Q1 24 | 31.4% | — |
| Q4 25 | 4.8% | 4.4% | ||
| Q3 25 | 1.1% | 2.8% | ||
| Q2 25 | 3.1% | 2.8% | ||
| Q1 25 | 3.7% | 3.0% | ||
| Q4 24 | 0.4% | 2.3% | ||
| Q3 24 | 1.2% | 0.5% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 1.0% | — |
| Q4 25 | 1.73× | — | ||
| Q3 25 | -0.88× | -1.58× | ||
| Q2 25 | 0.76× | -31.91× | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 1.73× | 0.61× | ||
| Q3 24 | 0.70× | 1.27× | ||
| Q2 24 | -0.43× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PKE
| North America | $16.8M | 97% |
| Other | $546.0K | 3% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
